Literature DB >> 28747147

Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder.

Kalliopi Pitarokoili1, Ralf Gold1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28747147     DOI： 10.1177/1352458517717090

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  3 in total

Review 1.  Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.

Authors:  Jan Traub; Silke Häusser-Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 2.  B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

Authors:  Jan Traub; Leila Husseini; Martin S Weber
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-06

3.  The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.

Authors:  Xiaofei Wang; Ziyan Shi; Zhengyang Zhao; Hongxi Chen; Yanlin Lang; Lingyao Kong; Xue Lin; Qin Du; Jiancheng Wang; Hongyu Zhou
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.